The same claims a jury found mobile carrier Sprint liable of infringing were later held invalid under Section 101 by the Federal Circuit in an appeal brought by cell provider T-Mobile. The judgment against Sprint had not been made final. Case date: 01 February 2019 Case number: No. 2018-1108 Court: United States Court of Appeals, Federal Circuit…

For manufacturers of biologics and biosimilars facing potential patent litigation in the U.S., the Biologics Price Competition and Innovation Act (BPCIA) imposes a complex statutory scheme that restricts the timing and control of disputes in federal district court. Biosimilar applicants who find themselves on the receiving end of a potential patent infringement complaint in district…

Patent claims relating to a virus-protection software to filter e-mail and electronic files are merely generic computer functions and not covered by a patent-eligible concept, the U.S. Court of Appeals for the Federal Circuit has ruled. In affirming a decision of the federal district court in Seattle, Washington to dismiss the patent infringement case brought…

The U.S. Court of Appeals for the Federal Circuit has denied attorney fees to a medical device manufacturer in a dispute relating to an expandable surgical reamer patent, ruling that the district court did not abuse its discretion in denying the prevailing defendant’s motion for attorney fees. The district court rejected the plaintiff’s proposed claim…

The U.S. Court of Appeals for the Federal Circuit has affirmed a $139.8 million jury verdict in favor of Sprint Communications against Time Warner for infringement of five Sprint patents related to VoIP technology. The appeals court concluded that the district properly admitted evidence relating to the jury verdict in an earlier, related case brought…

The assignor of a patented network security logging device that “broadcast” network security threats was not estopped from initiating an inter partes review of the patent, the U.S. Court of Appeals for the Federal Circuit has determined. However, the court also ruled that the Patent Trial and Appeal Board, in invalidated some of the patent’s…

A company that claimed a competitor misappropriated its trade secrets involving invoicing and job productivity software could proceed on its Louisiana Uniform Trade Secrets Act (LUTSA) and some of its common law conversion claims, the U.S. Court of Appeals for the Fifth Circuit ruled, reversing in part the district court’s dismissal of the claims. The…

Substantial evidence did not support the Patent Trial and Appeal Board’s finding that patentee LiquidPower Specialty Products Inc. (“LSPI”) failed to establish nexus, and thus the PTAB erred in not weighing LSPI’s objective evidence of non-obviousness in its decision invalidating a patent related to polymers added to crude oil, the U.S. Court of Appeals for…

Concluding that the asserted claims of patents relating to dosing and administration of the drug Copaxone used to treat multiple sclerosis are obvious, the U.S. Court of Appeals the Federal Circuit has affirmed a decision by the federal district court in Delaware invalidating the patents, handing a major victory to generic drug manufacturers. The Federal…